NCT02264288Phase 2Terminated

Efficacy and Safety of Intramuscular PDA-002 in Subjects With Diabetic Foot Ulcer With and Without PAD.

Study sponsor: Celularity Incorporated

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2018-02-27Actual
Enrollment · participants159Actual
Source updated2026-06-12Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Complete wound closure of the index ulcer Measure: Safety (adverse events [type, frequency, and severity of AEs, and relationship of AEs to study drug], laboratory abnormalities, and hospitalizations. After: Measure: Percentage of Subjects With Complete Wound Closure of the Index Ulcer Within 3 Months.

Primary completion date changed

Before: 28 Feb 2018. After: 27 Feb 2018.

Check registry source